GT Biopharma, Inc. entered into an Amendment to Settlement and Investment Agreement with Cytovance Biologics, increasing the limit on Cytovance's ownership of shares from 4.9% to 9.9% of GT Biopharma's outstanding shares.
AI Assistant
GT BIOPHARMA INC
2024
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.